On February 3, the result of the fourth batch of national volume-based procurement (VBP) was announced, and the competition results of the antidepressant drug duloxetine were settled. The results show that Qingdao Baheal Pharmaceutical Co., Ltd (Baheal Pharma), a subsidiary of Baheal Pharmaceutical Group, won the competition with the price of RMB 8.25 per box for Duloxetine Hydrochloride Enteric Capsules Nishu (20mg*14 capsules).

From January 10th, Qingdao officially entered the annual "two sessions time". Delegates and members focus on health, education, transportation, urban construction and other areas of people's livelihood and economic concerns, and participate in politics.The year 2020 is an extraordinary year, but it is difficult, more courageous. The spread of the epidemic has caused the value of life and health to be re-examined. The GDP ratio and growth rate of the health industry have increased against the tre

On December 19, Baheal Pharmaceutical Group was awarded the 2020 Shandong Province "Quality Lu Medicine" Construction Demonstration Enterprise Award by Shandong Province Pharmaceutical Industry Association; on December 21, Qingdao Baheal Medical Inc. (hereinafter referred to as "Baheal Medical"), a subsidiary of the Group, was awarded the "2020 Most Influential Enterprise in Pharmaceutical Industry".

On December 16, Astellas Pharma (China) Inc. and Baheal Medical Inc. held XOSPATA® (gilteritinib) import and distribution strategic signing ceremony. This will lay the foundation for the first cooperation between the two sides in the field of imported drugs.Baheal has already partnered with Astellas before on Harnal® and Feburic® to provide health services to Chinese patients. This time, the two sides will work together again for XOSPATA enter into the Chinese market, which will fill the gap

Shanghai, November 5, 2020 – Abbott and Qingdao Baheal Medical INC. formally signed an agreement in Shanghai during the Expo. Through the omni-channel commercial platform, Baheal will help high-quality products and efficient treatment programs reach patients smoothly and accurately, improve patients' experience of drug purchase and quality of life, and make good drugs benefit more patients.Jin Fangqian, general manager of Abbott's pharmaceutical business in China, and Fu Gang, chairman of Baheal